OCI-Ly19Homo sapiens (Human)Cancer cell line
Also known as: LY19, Ly19, OCILy19, OCILY19, OCILY-19, OCI Ly19, OCI-Ly 19, OCI-LY-19, OCI-LY19
Quick Overview
Human B-cell lymphoma cell line for cancer research
Detailed Summary
Research Applications
Key Characteristics
Basic Information
Database ID | CVCL_1878 |
---|---|
Species | Homo sapiens (Human) |
Tissue Source | Bone marrow[UBERON:UBERON_0002371] |
Donor Information
Age | 27 |
---|---|
Age Category | Adult |
Sex | Female |
Disease Information
Disease | Diffuse large B-cell lymphoma |
---|---|
Lineage | Lymphoid |
Subtype | Diffuse Large B-Cell Lymphoma, NOS |
OncoTree Code | DLBCLNOS |
DepMap Information
Source Type | DSMZ |
---|---|
Source ID | ACH-000124_source |
Known Sequence Variations
Type | Gene/Protein | Description | Zygosity | Note | Source |
---|---|---|---|---|---|
MutationSimple | NRAS | p.Gln61Lys (c.181C>A) | Unspecified | Acquired during resistance selection process | PubMed=26214590 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
The LL-100 panel: 100 cell lines for blood cancer studies.";
MacLeod R.A.F., Nagel S., Steube K.G., Uphoff C.C., Drexler H.G.
Sci. Rep. 9:8218-8218(2019).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Nature 568:511-516(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Screening human cell lines for viral infections applying RNA-Seq data analysis.
Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.
PLoS ONE 14:E0210404-E0210404(2019).
Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.
Yang H.H., Koeffler H.P.
BMC Cancer 18:940.1-940.13(2018).
Strategic therapeutic targeting to overcome venetoclax resistance in aggressive B-cell lymphomas.
Medeiros L.J., Ford R.J. Jr., Nomie K., Zhang L., Wang M.
Clin. Cancer Res. 24:3967-3980(2018).
Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma.
Pham L.V.
Oncotarget 9:346-360(2018).
Characterization of human cancer cell lines by reverse-phase protein arrays.
Liang H.
Cancer Cell 31:225-239(2017).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
Subtype-specific addiction of the activated B-cell subset of diffuse large B-cell lymphoma to FOXP1.
Tucker H.O.
Proc. Natl. Acad. Sci. U.S.A. 113:E577-E586(2016).
Malignant hematopoietic cell lines: in vitro models for double-hit B-cell lymphomas.
Drexler H.G., Eberth S., Nagel S., MacLeod R.A.F.
Leuk. Lymphoma 57:1015-1020(2016).
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Loewer M., Sahin U., Castle J.C.
Genome Med. 7:118.1-118.7(2015).
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
OncoImmunology 3:e954893.1-e954893.12(2014).
A resource for cell line authentication, annotation and quality control.
Neve R.M.
Nature 520:307-311(2015).
A comprehensive transcriptional portrait of human cancer cell lines.
Settleman J., Seshagiri S., Zhang Z.-M.
Nat. Biotechnol. 33:306-312(2015).
High-throughput RNA sequencing-based virome analysis of 50 lymphoma cell lines from the Cancer Cell Line Encyclopedia project.
O'Grady T., Baddoo M., Fewell C., Renne R., Flemington E.K.
J. Virol. 89:713-729(2015).
Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing.
Marra M.A.
Blood 122:1256-1265(2013).
Genetic heterogeneity of diffuse large B-cell lymphoma.";
Dunson D.B., Dave S.S.
Proc. Natl. Acad. Sci. U.S.A. 110:1398-1403(2013).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.
Kutok J.L., Shipp M.A.
Blood 116:3268-3277(2010).
Detection of EBV, HBV, HCV, HIV-1, HTLV-I and -II, and SMRV in human and other primate cell lines.
Uphoff C.C., Denkmann S.A., Steube K.G., Drexler H.G.
J. Biomed. Biotechnol. 2010:904767.1-904767.23(2010).
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.
Cook J.R., Weisenburger D.D., Chan W.-C., Pierce S.K., Staudt L.M.
Nature 463:88-92(2010).
Copy number abnormalities, MYC activity, and the genetic fingerprint of normal B cells mechanistically define the microRNA profile of diffuse large B-cell lymphoma.
Robetorye R.S., Aguiar R.C.T.
Blood 113:6681-6690(2009).
p53 mutations, c-myc and bcl-2 rearrangements in human non-Hodgkin's lymphoma cell lines.
Chang H., Blondal J.A., Benchimol S., Minden M.D., Messner H.A.
Leuk. Lymphoma 19:165-171(1995).
The (2;5)(p23;q35) translocation in cell lines derived from malignant lymphomas: absence of t(2;5) in Hodgkin-analogous cell lines.
Quentmeier H., Drexler H.G.
Leukemia 10:142-149(1996).